Effects of BAG956 on PKC412-sensitive and PKC412-resistant mutant FLT3-expressing cells, alone and in combination with rapamycin. (A) Effect of BAG956 on proliferation of PKC412-sensitive and PKC412-resistant mutant FLT3-expressing Ba/F3 cells after approximately 3 days of treatment. (B) Investigation of the effect of the combination of BAG956 and rapamycin on proliferation of Ba/F3-FLT3-ITD cells after approximately 3 days of treatment. (C) Investigation of the effect of combination of BAG956 and rapamycin on proliferation of Ba/F3-N676D cells after approximately 3 days of treatment. (C) Investigation of effect of combination of BAG956 and rapamycin on proliferation of Ba/F3-G697R cells after approximately 3 days of treatment. Concentrations of BAG956 used: 0, 0.0275 (25% IC₅₀), 0.055 (50% IC₅₀), 0.11 (100% IC₅₀), 0.22 (200% IC₅₀), 0.44 (400% IC₅₀) μM. Concentrations of rapamycin used: 0, 0.00 025 (25% IC₅₀), 0.0005 (50% IC₅₀), 0.001 (100% IC₅₀), 0.002 (200% IC₅₀), 0.004 (400% IC₅₀) μM.